Inactive Instrument

Fresenius Kabi Oncology Ltd Share Price

Equities

End-of-day quote NSE India S.E. Other stock markets
- ^INR	-

2016	AstraZeneca sells rights to anaesthetics for up to $770 million	RE
2015	Fresenius SE KGaA : Kabi sells German oncology compounding business	RE

AstraZeneca sells rights to anaesthetics for up to $770 million	09/16/09	RE
Fresenius SE KGaA : Kabi sells German oncology compounding business	16/15/16	RE
Fresenius Kabi Oncology Ltd : India revokes GSK cancer drug patent in latest Big Pharma blow	02/13/02	RE
Fresenius Kabi Oncology Ltd : India board revokes GSK patent on breast cancer drug Tykerb	02/13/02	RE

Managers	Title	Age	Since
Arvind Kumar Sharma CEO	Chief Executive Officer	-	01/18/01
Rahul Sharma DFI	Director of Finance/CFO	-	-
Maria Gobbi CHM	Chairman	-	13/14/13

Members of the board	Title	Age	Since
Michael Schönhofen BRD	Director/Board Member	63	11/08/11
Nikhil Kulshreshtha BRD	Director/Board Member	-	21/07/21
Maria Gobbi CHM	Chairman	-	13/14/13

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	111B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-2.68%	21.93B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-5.61%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-10.09%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.45B